Clinical trial NCT04216160: Skin Acceptance and Efficacy Assessment of a Topical Product in Acne Treatment When Compared to a Placebo.
Official title: Skin Acceptance and Efficacy Assessment of a Topical Product in Acne Treatment When Compared to a Placebo, Under Normal Use Conditions.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acne Vulgaris
Lead sponsor: YUN NV
Sponsor class: INDUSTRY
Collaborators: name: Allergisa Pesquisa Dermato-Cosmetica LTDA
First posted: 2020-01-02
Enrollment: 80
Sex: ALL
Minimum age (years): 12
Maximum age (years): 35
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this study the topical use of cream with live probiotic bacteria was evaluated for its efficacy in reducing acne symptoms and its effect on the skin microbiota on patients with acne vulgaris. Patients with mild to moderate acne used the probiotic cream for 8 weeks and clinical evaluation and microbiological sampling was done at start, 2, 4, 8 and 12 weeks (after 4 weeks without use of the product). Next-Generation Sequencing is used to analyze the skin microbiota of the patients.

Detailed description: Probiotics are live micro-organisms which when administered in adequate amounts can exert a health benefit on the host. This health-promoting effects have been extensively studied in the gastrointestinal niche but it becomes more and more clear that other niches are also interesting for the potential of probiotics. Recent breakthroughs in 'next generation sequencing' (NGS) technologies are making it now possible to map the microbiota after DNA extraction, which is very interesting for bacteria that are not or difficult to cultivate. The research into the microbiota of the skin with such new NGS technologies shows that there is also an equilibrium in the skin composition of the microbiota and that there is a disturbance of the skin microbiota in acne. Acne vulgaris is known as a multifactorial condition, both hormonal triggers and environmental factors play a role. However, it is also known that Cutibacterium acnes and Staphylococcus spp. play an important role in the inflammation of the sebaceous gland follicles. Therefore, probiotic strains with antipathogenic activity against these bacteria and suitable for application to the skin are potentially able to restore the balance of the skin microbiota and reduce acne symptoms. The main objective of this study was to verify the skin acceptance and efficacy of the cream with live probiotic bacteria for acne treatment in comparison with a placebo. More specifically to evaluate the effect of the 'live' Lactobacillus species as 'active ingredient' in relation to acne symptoms and skin microbiome modulation.

Eligibility criteria: Inclusion Criteria:

* Healthy skin in the test areas;
* Subjects willing and capable to follow the study rules and a fixed schedule;
* Ability of giving consent for participation in the study;
* Subjects with good health in general and good mental condition;
* Subjects who present at least 10 inflammatory lesions;
* Oily skin on the face (minimum sebumetry value 100µg/cm² on frontal area (mean: 3 measurements)).

Exclusion Criteria:

* Pregnancy or breastfeeding;
* Subjects who present severe acne;
* Subjects who present more than two nodular lesions;
* Subjects who changed their oral contraception method up to three months before the study beginning;
* Subjects who did acne hormonal treatment less than 6 months before the study;
* Subjects who did oral isotretinoïne treatment less than 1 month before the study;
* Subjects who did topical acne treatment less than 90 months before the study;
* Subjects who did aesthetic treatment less than 6 months before the study (like laser and peeling);
* Subjects who did treatment with antibiotics within the last 4 months;
* Simultaneous participation in different studies from external research institutes on the same test sites;
* Inadequate language proficiency (spoken and written);
* Participate in the study under the influence of alcohol and/or drugs as well as addiction;
* Severe psychological disease or intellectual disability of understanding the study;
* Severe disease (heart/circulatory/liver, kidney and lungs disease, severe diabetes mellitus) or chronic infections (hepatitis, HIV);
* Immune insufficiency;
* Current use of the following topical or systemic medications: corticosteroids, immunosuppressive and anti-histaminic drugs;
* Skin diseases: vitiligo, psoriasis, atopic dermatitis;
* Confirmed allergies to cosmetic components or previous responses of intolerance after the application of cosmetic products of the same category of the investigational products;
* Other diseases or medications that might directly interfere in the study or put the subject's health under risk.

Primary outcomes:
measure: Change of inflammatory lesions compared to placebo.
timeFrame: baseline, 2, 4 and 8 weeks of product use and 4 weeks without product use (Total 12 weeks).
measure: Change of inflammatory lesions compared to baseline.
timeFrame: baseline, 2, 4 and 8 weeks of product use and 4 weeks without product use (Total 12 weeks).
measure: Overall tolerance of the treatment
timeFrame: Baseline to week 12
Secondary outcomes:
Other outcomes:
Locations:
city: Campinas
country: Brazil
facility: Allergisa Pesquisa Dermato-Cosmética Ltda
state: SP
Study officials:
affiliation: Allergisa Pesquisa Dermato-Cosmética Ltda
name: Mariane Mosca
role: PRINCIPAL_INVESTIGATOR
References: